Related references
Note: Only part of the references are listed.ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
Naoki Iwanaga et al.
ISCIENCE (2022)
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu-Chyi Hwang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2022)
Therapeutic Fc-fusion proteins: Current analytical strategies
Bastiaan L. Duivelshof et al.
JOURNAL OF SEPARATION SCIENCE (2021)
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Colton J. Bracken et al.
NATURE CHEMICAL BIOLOGY (2021)
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
Hristo L. Svilenov et al.
ANTIVIRAL RESEARCH (2021)
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Tyler N. Starr et al.
SCIENCE (2021)
Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
Cong Xu et al.
SCIENCE ADVANCES (2021)
The search for animals harbouring coronavirus — and why it matters
Smriti Mallapaty
NATURE (2021)
SARS-CoV-2 evolution during treatment of chronic infection
Steven A. Kemp et al.
NATURE (2021)
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen et al.
NATURE MEDICINE (2021)
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Xuping Xie et al.
NATURE MEDICINE (2021)
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Federico Bertoglio et al.
NATURE COMMUNICATIONS (2021)
Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia
Supaporn Wacharapluesadee et al.
NATURE COMMUNICATIONS (2021)
Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
Tuemay Capraz et al.
ELIFE (2021)
His345 mutant of angiotensin-converting enzyme 2 (ACE2) remains enzymatically active against angiotensin II
Pan Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
REPLY TO LIU ET AL.: Specific mutationsmatter in specificity and catalysis in ACE2
Jeff Glasgow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike
Ahmad Reza Mehdipour et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
Huihui Mou et al.
PLOS PATHOGENS (2021)
SARS-CoV-2 evolution and vaccines: cause for concern?
Thomas C. Williams et al.
LANCET RESPIRATORY MEDICINE (2021)
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
Mathieu Ferrari et al.
JOURNAL OF VIROLOGY (2021)
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Meng Yuan et al.
SCIENCE (2021)
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
Yusuke Higuchi et al.
NATURE COMMUNICATIONS (2021)
Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
Zhaoyong Zhang et al.
CELL DISCOVERY (2021)
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
Haibo Zhang et al.
INTENSIVE CARE MEDICINE (2020)
A novel coronavirus outbreak of global health concern
Chen Wang et al.
LANCET (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan et al.
SCIENCE (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Michael Letko et al.
NATURE MICROBIOLOGY (2020)
Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection
Junwen Luan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System Celebrating the 20th Anniversary of the Discovery of ACE2
Mahmoud Gheblawi et al.
CIRCULATION RESEARCH (2020)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors
Iziah E. Sama et al.
EUROPEAN HEART JOURNAL (2020)
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu et al.
SCIENCE (2020)
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Changhai Lei et al.
NATURE COMMUNICATIONS (2020)
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Junyi Guo et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
FcγR Binding and ADCC Activity of Human IgG Allotypes
Steven W. de Taeye et al.
FRONTIERS IN IMMUNOLOGY (2020)
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi et al.
NATURE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins
Kangpeng Xiao et al.
NATURE (2020)
Infection of dogs with SARS-CoV-2
Thomas H. C. Sit et al.
NATURE (2020)
被撤回的出版物: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (Publication with Expression of Concern. See vol. 382, pg. 2464, 2020) (Retracted article. See vol. 382, pg. 2582, 2020)
Mandeep R. Mehra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Nikolai Eroshenko et al.
NATURE BIOTECHNOLOGY (2020)
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
Kui K. Chan et al.
SCIENCE (2020)
SARS-CoV-2 and Three Related Coronaviruses Utilize Multipke ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
Yujun Li et al.
JOURNAL OF VIROLOGY (2020)
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions
Abdollah Jafarzadeh et al.
LIFE SCIENCES (2020)
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
Donald J. Benton et al.
NATURE (2020)
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Anum Glasgow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020
Cordelia Manickam et al.
PLOS PATHOGENS (2020)
Human recombinant soluble ACE2 in severe COVID-19
Alexander Zoufaly et al.
LANCET RESPIRATORY MEDICINE (2020)
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Mohamed A. Alfaleh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein
Lorenzo Casalino et al.
ACS CENTRAL SCIENCE (2020)
Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects
Pan Liu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
Lucy van Dorp et al.
NATURE COMMUNICATIONS (2020)
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Yiska Weisblum et al.
ELIFE (2020)
Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region
Michael W. Handlogten et al.
MABS (2020)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors
Iziah E. Sama et al.
EUROPEAN HEART JOURNAL (2020)
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2020)
A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
Xiaoniu Miao et al.
MABS (2020)
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
Christophe Dumet et al.
MABS (2019)
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
Elisabeth A. van Erp et al.
FRONTIERS IN IMMUNOLOGY (2019)
Distribution of FcRn Across Species and Tissues
Sari Latvala et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2017)
Structural Basis for Receptor Selectivity by the Whitewater Arroyo Mammarenavirus
Amir Shimon et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Akram Khan et al.
CRITICAL CARE (2017)
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development
Laura I. Salazar-Fontana et al.
AAPS JOURNAL (2017)
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
Felix Unverdorben et al.
MABS (2016)
Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus
Hongjing Gu et al.
SCIENTIFIC REPORTS (2016)
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Jonathan T. Sockolosky et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
William R. Strohl
BIODRUGS (2015)
The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation
John-Paul Silva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Anti-infective immunoadhesins from plants
Keith Wycoff et al.
PLANT BIOTECHNOLOGY JOURNAL (2015)
ACE in the hole
Friedrich C. Luft
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
Mihalis S. Kariolis et al.
NATURE CHEMICAL BIOLOGY (2014)
Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus
Fumihiko Yasui et al.
VIROLOGY (2014)
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
Zhen Zou et al.
NATURE COMMUNICATIONS (2014)
Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
Manuel Haschke et al.
CLINICAL PHARMACOKINETICS (2013)
Fc-fusion proteins: new developments and future perspectives
Daniel M. Czajkowsky et al.
EMBO MOLECULAR MEDICINE (2012)
Secondary interactions involving zinc-bound ligands: Roles in structural stabilization and macromolecular interactions
Frances Namuswe et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Saccharomyces cerevisiae in directed evolution An efficient tool to improve enzymes
David Gonzalez-Perez et al.
BIOENGINEERED (2012)
A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry
Ana Shulla et al.
JOURNAL OF VIROLOGY (2011)
Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
Ilona Glowacka et al.
JOURNAL OF VIROLOGY (2011)
Immunogenicity and other problems associated with the use of biopharmaceuticals
Michael G. Tovey et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2011)
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2
Shutoku Matsuyama et al.
JOURNAL OF VIROLOGY (2010)
Stability of IgG isotypes in serum
Ivan R. Correia
MABS (2010)
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Chichi Huang
CURRENT OPINION IN BIOTECHNOLOGY (2009)
The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity
Salit Tzaban et al.
JOURNAL OF CELL BIOLOGY (2009)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Y Imai et al.
NATURE (2005)
Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis
JL Guy et al.
FEBS JOURNAL (2005)
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway
AJ Bitonti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas
RAS Santos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase
C Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors
AJ Turner et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2002)
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study
WT Shearer et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
M Donoghue et al.
CIRCULATION RESEARCH (2000)
Function and mechanism of zinc metalloenzymes
KA McCall et al.
JOURNAL OF NUTRITION (2000)